










































Perioperative haemodynamic therapy for major gastrointestinal
surgery
Citation for published version:
Ryan, EG, Harrison, EM, Pearse, RM & Gates, S 2019, 'Perioperative haemodynamic therapy for major
gastrointestinal surgery: the effect of a Bayesian approach to interpreting the findings of a randomised
controlled trial', BMJ Open, vol. 9, no. 3, pp. e024256. https://doi.org/10.1136/bmjopen-2018-024256
Digital Object Identifier (DOI):
10.1136/bmjopen-2018-024256
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 12. Sep. 2019
1Ryan EG, et al. BMJ Open 2019;9:e024256. doi:10.1136/bmjopen-2018-024256
Open access 
Perioperative haemodynamic therapy 
for major gastrointestinal surgery: the 
effect of a Bayesian approach to 
interpreting the findings of a 
randomised controlled trial
Elizabeth G Ryan,1,2 Ewen M Harrison,3 Rupert M Pearse,4 Simon Gates1,2
To cite: Ryan EG, Harrison EM, 
Pearse RM, et al.  Perioperative 
haemodynamic therapy for 
major gastrointestinal surgery: 
the effect of a Bayesian 
approach to interpreting the 
findings of a randomised 
controlled trial. BMJ Open 
2019;9:e024256. doi:10.1136/
bmjopen-2018-024256
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
024256).
EGR and EMH contributed 
equally.
Received 17 May 2018
Revised 30 January 2019
Accepted 31 January 2019
1Warwick Clinical Trials Unit, 
University of Warwick, Coventry, 
UK
2Cancer Research UK Clinical 
Trials Unit, University of 
Birmingham, Birmingham, UK
3Clinical Surgery, University of 
Edinburgh, Edinburgh, UK
4Barts and the London School 
of Medicine & Dentistry, Queen 
Mary University of London, 
London, UK
Correspondence to
Dr Elizabeth G Ryan;  
 E. G. Ryan@ bham. ac. uk
Research
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY. 
Published by BMJ.
AbstrACt
Objective The traditional approach of null hypothesis testing 
dominates the design and analysis of randomised controlled 
trials. This study aimed to demonstrate how a simple 
Bayesian analysis could have been used to analyse the 
Optimisation of Perioperative Cardiovascular Management 
to Improve Surgical Outcome (OPTIMISE) trial to obtain more 
clinically interpretable results.
Design, setting, participants and interventions The 
OPTIMISE trial was a pragmatic, multicentre, observer-
blinded, randomised controlled trial of 734 high-risk 
patients undergoing major gastrointestinal surgery in 17 
acute care hospitals in the UK. Patients were randomly 
allocated to a cardiac output-guided haemodynamic 
therapy algorithm for intravenous fluid and inotropic 
drug administration during and in the 6 hours following 
surgery (n=368) or to standard care (n=366). The primary 
outcome was a binary outcome consisting of a composite 
of predefined 30-day moderate or major complications and 
mortality.
Methods We repeated the primary outcome analysis of 
the OPTIMISE trial using Bayesian statistical methods to 
calculate the probability that the intervention was superior, 
and the probability that a clinically relevant difference 
existed. We explored the impact of a flat prior and an 
evidence-based prior on our analyses.
results Although OPTIMISE was not powered to detect a 
statistically significant difference between the treatment 
arms for the observed effect size (relative risk=0.84, 
95% CI 0.70 to 1.01; p=0.07), by using Bayesian analyses 
we were able to demonstrate that there was a 96.9% (flat 
prior) to 99.5% (evidence-based prior) probability that the 
intervention was superior to the control.
Conclusions The use of a Bayesian analytical approach 
provided a different interpretation of the findings of the 
OPTIMISE trial (compared with the original frequentist 
analysis), and suggested patient benefit from the 
intervention. Incorporation of information from previous 
studies provided further evidence of a benefit from the 
intervention. Bayesian analyses can produce results that 
are more easily interpretable and relevant to clinicians and 
policy-makers.
trial registration number ISRCTN04386758; Post-
results.
IntrODuCtIOn 
The traditional statistical approach of null 
hypothesis testing dominates clinical trial 
design and analysis. In this frequentist frame-
work, conclusions are drawn using p values 
and CIs which have been generated to test 
a specific hypothesis (usually a null hypoth-
esis of exactly zero treatment difference). It 
requires that a correct conclusion be drawn 
with a high level of probability (statistical 
power) from a notional set of repetitions of 
the trial.
The problems with this approach are well 
described.1–4 Frequentist results (p values and 
CIs) do not have simple or intuitive interpre-
tations, and have often been misused and 
misinterpreted in clinical trials.2 Randomised 
controlled trial results are often divided into 
‘significant’ and ‘non-significant’, usually 
based on a p value <0.05. A statistically non-sig-
nificant result for the primary endpoint is 
generally interpreted as the new treatment 
being ‘unsuccessful’.5 6 This is often an incor-
rect interpretation, and was highlighted by 
Altman and Bland,7 ‘absence of evidence is 
strengths and limitations of this study
 ► The use of a Bayesian analytical approach pro-
vided a different interpretation of the findings of 
the Optimisation of Perioperative Cardiovascular 
Management to Improve Surgical Outcome  trial 
(compared with the original frequentist analysis).
 ► The Bayesian approach avoids the dichotomisation 
of results that occurs in significance testing.
 ► Bayesian analyses can produce results that are 
more easily interpretable and relevant to clinicians 
and policy-makers.
 ► The analysis only used simple Bayesian methods 
and more sophisticated approaches can be used, 
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not evidence of absence’. Randomised controlled trials 
are regarded as the gold standard of evidence and their 
results often inform clinical guidelines and practice. The 
misuse and misinterpretation of p values (and CIs) may 
result in the abandonment of potentially beneficial treat-
ments. McShane et al4 recommended that null hypothesis 
testing should be abandoned altogether, and one peer-re-
viewed journal has banned its use.8
Bayesian statistical methods provide an alternative 
framework for statistical modelling, and are increas-
ingly being used in randomised controlled trials.9–11 The 
Bayesian approach can be used at the design stage and for 
data analysis. Bayesian statistics provide a formal method 
for combining pre-existing information with data that are 
collected in the clinical trial into the analysis so that the 
current state of knowledge can be updated. This is partic-
ularly useful for clinical research given that advances in 
healthcare usually occur through incremental gains in 
knowledge. The Bayesian approach may also provide 
results that are easier to interpret than the frequentist 
approach since it computes the probability of various 
values of the treatment effect, given the data.
Pre-existing information is incorporated into the anal-
ysis via a prior distribution. This is a probability distribution 
that accounts for uncertainty in an unknown parameter, 
for example, the treatment effect, before the data from 
the clinical trial has been incorporated. The frequentist 
approach assumes the parameter to have a fixed, but 
unknown value. Some are put off by this aspect of the 
Bayesian approach, expressing a concern that it is not 
scientifically objective. However, any statistical method, 
including traditional frequentist methods, involve subjec-
tive choices. For instance, the arbitrarily set 5% signifi-
cance level in the frequentist approach. Moreover, 
so-called non-informative priors can be used when there is 
little reliable previous information, or when one would 
prefer to numerically mimic a frequentist analysis and 
avoid introducing external information into the analysis. 
These are often used as a default prior.
When clinical trial data are observed, the prior distri-
bution is updated to become the posterior distribution, 
which summarises the current knowledge. The posterior 
distribution of the treatment effect provides the relative 
credibility of the range of treatment effect values, given 
the trial data. Calculation of the posterior distribution 
can often be straightforward; however, many practical 
examples require computationally intensive approaches. 
Part of the reason Bayesian statistics is becoming more 
popular is due to the advances in computing power and 
computational techniques. The posterior distribution 
can be used to answer questions of direct relevance to 
decision-making, such as ‘What is the probability that 
the new treatment is more successful than the current 
treatment?’ Frequentist methods are limited as to what 
research questions they can answer, and cannot directly 
provide answers to clinically important questions.
Rather than using CIs, Bayesian statistics can use cred-
ible intervals, which provide a range of values for the 
treatment effect for a certain level of posterior proba-
bility. The highest posterior density interval (HDI) is the 
narrowest type of credible interval available for a spec-
ified probability. Although frequentist CI and Bayesian 
HDI may sometimes be numerically similar, their inter-
pretation is different. A 95% HDI says, given the observed 
data, there is a 95% probability that the true parameter 
value falls within this interval. The frequentist interpre-
tation of a 95% CI says, if this trial were to be repeated 
many times and CIs were calculated, 95% of these inter-
vals would contain the true parameter value.
In this article we provide an example of how a simple 
Bayesian analysis of a binary primary outcome could 
have been used instead of (or in addition to) traditional 
frequentist methods, to give a better insight into the clin-
ical application of the results. We analyse a randomised 
controlled trial of two treatments for patients undergoing 
major gastrointestinal surgery, to arrive at a conclusion 
that may be more clinically interpretable and useful, and 
also provide a more positive message from the trial.
MethODs
Data and study design
The Optimisation of Peri-operative Cardiovascular 
Management to Improve Surgical Outcome (OPTIMISE) 
trial12 was a pragmatic, observer-blinded, multi-centre, 
randomised controlled trial of 734 high-risk patients 
(aged 50 years and older) that had undergone major 
gastrointestinal surgery in 17 acute care hospitals in 
the UK. Previous research suggested that postoperative 
outcomes may be improved by the use of cardiac output 
monitoring to guide the administration of intravenous 
fluid and inotropic drugs in the time around surgery.13 
Patients were randomly assigned (1:1) to a cardiac output-
guided haemodynamic therapy algorithm for intravenous 
fluid and inotropic drug administration during and in 
the 6 hours following surgery (intervention; n=368) or to 
usual care (n=366). The primary outcome was a composite 
of predefined 30-day moderate or major complications 
and mortality.
The primary outcome occurred in 158/364 (43.41%) 
usual care and 134/366 (36.61%) intervention patients. 
At first glance, this would suggest that the results favour 
the intervention group compared with usual care. Using 
the traditional frequentist approach, the relative risk (RR) 
was found to be 0.84 (95% CI 0.7 to 1.01) and absolute risk 
reduction was 6.79% (95% CI −0.30% to 13.89%), with 
p=0.07. This was interpreted as there being insufficient 
evidence that the RR for complication/death at 30 days is 
different to 1. Thus, the authors concluded, “Use of this 
cardiac output-guided, hemodynamic therapy algorithm 
was not associated with a significant reduction in the 
composite primary outcome of moderate or major post-
operative complications at 30 days following surgery.”12 
A difference exists between the groups, but this was not 
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Patient involvement
Patients were not involved in the re-analysis of the OPTI-
MISE trial.
statistical methods
By repeating the same analysis using Bayesian methods 
we can find an alternative way to model and interpret 
these data. The Bayesian analysis involves specifying a 
prior distribution for the primary outcome rate in each 
treatment arm, and using the OPTIMISE trial data to 
update these prior distributions to become posterior 
distributions. From the posterior distributions we calcu-
late the RR or absolute risk difference and 95% HDI. We 
also use the posterior distribution to calculate the proba-
bility that the intervention is superior (RR <1 or absolute 
risk difference <0).
We can extend this idea by specifying a clinically signif-
icant effect size. For instance, a group of clinicians or 
patients could decide that a RR must differ from the null 
by, say, 10% to be clinically significant. This ‘region of 
practical equivalence’ (ROPE) can be used to make prob-
ability statements about the likely clinical significance of 
effect sizes. For illustrative purposes we specify the ROPEs 
to be 0.9–1.1 for the RR and −0.05 to 0.05 (−5% to 5%) 
for the absolute risk difference. These ROPEs may not be 
reasonable in practice, and should be developed based 
on clinician, patient and health economists’ feedback.
Additionally, we can simulate the outcomes of future 
patients using the updated estimates of the probabilities 
of having the primary outcome (from the posterior distri-
bution) to predict the proportion of cases in which using 
the intervention would result in no complication/death 
while not using the intervention would.
We used two different types of prior distributions in 
separate analyses to check the robustness of our conclu-
sions to our prior distribution assumptions. We used Beta 
distributions for the priors as these allowed the posterior 
distribution to be calculated more easily for our data. The 
sum of the two shape parameters in the Beta distribution 
provides an estimate of the effective sample size that the 
prior distribution provides, that is, how much informa-
tion it contributes.
Initially we used a flat prior for both arms, the beta(1,1) 
distribution. This assumes that the prior distributions for 
the proportions for the composite outcome are uniform 
in each arm (see figure 1, top panel), that is, all values 
between 0 and 1 are equally likely a priori. While some 
values of the composite outcome rate are more likely 
than others, a flat prior may be used so that inferences 
from the posterior are driven by the trial data and prob-
abilistic statements about the treatment effect can still 
be made. This prior contributes one additional patient 
with no complications and one patient with a complica-
tion/death. The results from this prior are unlikely to 
give different results to the original analysis, in terms of 
the RR and absolute risk difference, but the interpreta-
tions are likely to differ. A weakness of this approach is 
that too much prior probability is placed on extremely 
unlikely outcomes, that is, the prior described gives an 
equal weighting to the probability of all patients having a 
complication and no patients having a complication.
When the results from the OPTIMISE trial were incor-
porated into an updated meta-analysis, it was found that 
the intervention reduced the incidence of 30-day compli-
cations/death following surgery: 31.52% (intervention) 
versus 41.60% (control), RR 0.77 (95% CI 0.71 to 0.83).12 
We wanted to combine the previous information with 
the OPTIMISE trial data so that more precise treatment 
effect estimates could potentially be obtained and to pull 
the data away from inappropriate inferences. Therefore, 
an evidence-based prior was also specified using the 
results from a pre-existing systematic review12 13 which 
had information on both treatment arms (online supple-
mentary figures S1 and S2). Figure 1 shows the evidence-
based prior distributions for the control (middle panel) 
and intervention arm (bottom panel), where the distri-
bution for the primary outcome rate in the intervention 
arm is centred at a lower value. Further details on how 
these priors were derived are displayed in the online 
supplementary material. The evidence-based prior for 
the control arm contributed an effective sample size of 56 
patients, and the intervention arm prior contributed 66 
patients worth of information. With this additional infor-
mation, the RR and absolute risk difference may decrease 
in favour of the intervention, compared with the original 
analyses.
Figure 1 Prior distributions used in Bayesian re-analysis of 
Optimisation of Perioperative Cardiovascular Management 
to Improve Surgical Outcome. The top panel is a flat prior 
distribution, beta(1, 1), that was used for both treatment 
arms. The middle and bottom panels show the evidence-
based priors that were derived using a meta-analysis. The 
middle panel is the prior for the control arm (beta(24.26, 
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The Bayesian analysis was conducted in R V.3.4.1 and 
additional information on the algorithm settings and the 
code for the Bayesian analysis is available in the online 
supplementary material. Readers can perform the anal-
ysis here: https:// argoshare. is. ed. ac. uk/ bayesian_ two_ 
proportions/
results
The results differ slightly between the flat and evidence-
based priors, particularly for the probability of lying in 
the ROPE. Under the flat prior, the posterior mean RR is 
0.85 (95% HDI 0.70 to 1.00), which is approximately the 
same as the frequentist analysis. Using the evidence-based 
priors, the posterior mean RR is 0.81 (95% HDI 0.67 to 
0.95). The probability that the intervention group has a 
lower incidence of the composite endpoint is 96.9% and 
99.5%, assuming a flat and evidence-based prior, respec-
tively (figure 2A,B).
Based on the RR ROPE, the probability of the two arms 
being clinically equivalent was 24% and 9% under the flat 
and evidence-based priors, respectively. Alternatively, the 
probability of there being a clinically relevant difference 
in the RR of the composite endpoint between the two 
groups was 76% and 91% for the flat and evidence-based 
priors, respectively.
Using the flat prior, the posterior mean of the abso-
lute risk difference/reduction was 6.76% (95% HDI 
−0.30% to 13.80%), which is approximately the same as 
the frequentist analysis. Using the evidence-based prior, 
this value was 8.55% (95% HDI 2.00% to 15.00%). When 
the ROPE was defined as an absolute risk difference of 
−5% to 5%, the probabilities of the trial arms being equiv-
alent were 31% and 14% (69% and 86% probability of 
there being a clinically relevant difference) using the flat 
and evidence-based priors, respectively (see figure 2C,D).
The posterior probability of different RRs occurring is 
shown in figure 3A (flat prior) and figure 3B (evidence-
based prior). For example, in figure 3A, the probability 
that the RR <1 is 0.97, and the probability RR <0.8 is 0.28.
Using the Bayesian model, predictions were obtained 
from the posterior distribution for future patients. These 
found that the probability that a patient in the interven-
tion group did not have a complication/death when a 
patient in the control group did have a complication/
death was 27.56% (flat prior) and 28.49% (evidence-based 
prior). (The probability of a patient in the intervention 
group having a complication/death when a patient in the 
Figure 3 Posterior probability of specified effect sizes, using 
(A) flat prior, (B) evidence-based priors. The line shows the 
probability of the relative risk (RR) being lower than the values 
on the x-axis (ie, a bigger treatment effect). A RR <1 indicates 
that the primary outcome rate is smaller in the intervention 
arm compared with the control arm.
Figure 2 Posterior distributions of relative risk (RR) and 
absolute risk difference for the flat prior and evidence-
based priors. θ1 and θ2 are the composite outcome rates 
in the intervention and control arms, respectively. Posterior 
distribution of the RR of the primary outcome using (A) a 
flat prior, (B) evidence-based priors. A RR >1 indicates that 
the intervention is more harmful. Posterior distribution of the 
absolute risk difference in the primary outcome using (C) a 
flat prior (D) evidence-based priors. A positive value of the 
absolute risk difference indicates that the intervention is more 
harmful. The 95% highest posterior density interval (HDI) is 
shown as the thick black horizontal line with the boundaries 
written above the line. The region of practical equivalence 
(ROPE) is shown in red (with dotted vertical lines). The 
posterior probability of RR <1 and RR >1, and an absolute 
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control group did not was 20.77% and 19.59%, assuming 
a flat and evidence-based prior, respectively.)
DIsCussIOn
In this work we have performed a Bayesian re-analysis 
of the OPTIMISE trial12 to demonstrate how a Bayesian 
approach can more easily answer clinical questions of 
interest and inform decision making. Our conclusions 
from the analysis are given in terms of probabilities that a 
benefit exists. The Bayesian approach also enabled us to 
formally incorporate information from previous studies 
on the event rates for each arm and combine this informa-
tion with the OPTIMISE trial data. The principal finding 
of this analysis was that the use of a Bayesian analytical 
approach provided a different interpretation of the find-
ings of the OPTIMISE trial, suggesting patient benefit 
from the intervention.
The OPTIMISE trial was powered (at 90%) to detect a 
reduction in the primary outcome rate from 50% in the 
control group to 37.5% in the intervention group (RR 
0.75, absolute risk reduction 12.5%). The frequentist 
analysis conducted by Pearse et al12 identified no signifi-
cant difference for 30-day complications/death between 
the treatment arms and deemed the trial to be under-
powered. The Bayesian posterior mean estimates and 
95% HDI based on the flat priors gave similar results to 
the frequentist analysis as expected, with more optimistic 
results produced by the evidence-based prior. (Previous 
evidence had suggested that the intervention was supe-
rior.) The primary advantage here of using the Bayesian 
approach is that we can explicitly obtain the posterior 
distribution of the primary outcome rates for each arm, 
and from this the treatment effect distribution, which can 
be interpreted directly and intuitively. From these distri-
butions we can calculate the probability that the new treat-
ment is superior. A frequentist analysis, particularly of 
an underpowered trial, provides little help for clinicians 
to make the necessary decisions regarding future treat-
ment and also runs the risk of concluding no difference 
between treatments (based on a non-significant p value), 
even when there is in reality a useful difference. By incor-
porating previous information into the prior distribution, 
the Bayesian approach can provide more informative 
probabilistic statements about the treatment effect.
For a reasonably large trial, different priors should have 
little effect on the posterior distributions as the data are 
contributing a large amount of information, and gener-
ally outweigh the contribution of the prior information. 
In this study, altering the priors had little impact on the 
results, most likely due to the fairly large sample size. 
The evidence-based prior used information from 21 
small studies whose sample sizes ranged from 34 to 390 
patients and were mostly in favour of the intervention. 
The evidence-based prior for the control arm contrib-
uted 56 patients worth of information compared with the 
364 patients from OPTIMISE; the evidence-based prior 
for the intervention arm contributed 66 patients worth 
of information and the OPTIMISE trial contributed 366 
patients. The analyses which used the evidence-based 
priors obtained a slightly smaller RR and provided more 
certainty that the intervention was superior, compared 
with the flat priors. Since the previous studies were small 
studies, one may wish to down weight the influence of 
these studies in the prior to consider the risk of bias. Plots 
of the priors overlaid with the posteriors for the evidence-
based priors are provided in the supplementary material 
(online supplementary figure S3) and show that the prior 
for the intervention was too optimistic. This is likely due 
to the small size of many of the previous studies and the 
large degree of heterogeneity between studies. Publica-
tion bias may also be present.
The Bayesian analyses that we have presented here 
are simple, and repeat the primary analysis of the OPTI-
MISE trial to demonstrate the usefulness of the Bayesian 
approach. These analyses could be extended to allow for 
more complicated models, such as Bayesian hierarchical 
models that account for site-specific effects or to allow for 
covariate adjustment. A Bayesian analysis cannot salvage 
a badly designed or conducted trial. Instead, the Bayesian 
approach can be used to produce results that are more 
easily interpreted and avoids the dichotomisations that 
occur in significance testing.
COnClusIOn
Using the results from a standard statistical analysis, the 
OPTIMISE trial authors concluded that the use of the 
intervention compared with usual care did not signifi-
cantly reduce a composite outcome of 30-day complica-
tions and mortality.12 Although the trial was not powered 
to detect a statistically significant difference between 
the treatment arms for the observed effect size, by using 
Bayesian analyses we were able to demonstrate that the 
intervention was superior to the control with 96.9%–
99.5% probability. These results are much more clini-
cally useful than those that are given by the traditional 
approach.
Contributors EMH and EGR wrote the statistical code and performed the Bayesian 
analysis, interpreted the findings and wrote the manuscript. SG contributed to 
the writing of the manuscript. RMP was the CI for the OPTIMISE study, was the 
lead author on the primary OPTIMISE paper and contributed to the writing of the 
manuscript.
Funding  EGR and SG were supported by a Medical Research Council 
(MRC) Methodology Research Grant (Grant number: MR/N028287/1). SG is 
supported by a National institute of Health Research Senior Investigator Award 
(NF-SI-0616-10008). 
Competing interests RMP holds research grants, and has given lectures and/
or performed consultancy work for Nestle Health Sciences, BBraun, Medtronic, 
Glaxo Smithkline, Intersurgical, and Edwards Lifesciences, and is a member of the 
Associate editorial board of the British Journal of Anaesthesia. 
Patient consent for publication Not required.
ethics approval OPTIMISE was approved by the East London and City Research 
Ethics Committee and the Medical and Healthcare Products Regulatory Agency.
Provenance and peer review Not commissioned; externally peer reviewed.









pen: first published as 10.1136/bmjopen-2018-024256 on 7 March 2019. Downloaded from 
6 Ryan EG, et al. BMJ Open 2019;9:e024256. doi:10.1136/bmjopen-2018-024256
Open access 
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
reFerenCes
 1. Simmons JP, Nelson LD, Simonsohn U. False-positive psychology: 
undisclosed flexibility in data collection and analysis allows 
presenting anything as significant. Psychol Sci 2011;22:1359–66.
 2. Greenland S, Senn SJ, Rothman KJ, et al. Statistical tests, P values, 
confidence intervals, and power: a guide to misinterpretations. Eur J 
Epidemiol 2016;31:337–50.
 3. Wasserstein RL, Lazar NA. The ASA's Statement on p -Values: 
Context, Process, and Purpose. Am Stat 2016;70:129–33.
 4. McShane BB, Gal D, Gelman A, et al. Abandon statistical 
significance. arXiv 2017.
 5. Alderson P, Chalmers I. Survey of claims of no effect in abstracts of 
Cochrane reviews. BMJ 2003;326:475.
 6. Greenland S. Null misinterpretation in statistical testing and its 
impact on health risk assessment. Prev Med 2011;53:225–8.
 7. Altman DG, Bland JM. Statistics notes: absence of evidence is not 
evidence of absence. BMJ 1995;311:485.
 8. Trafimow D, Marks M. Editorial. Basic Appl Soc Psych 2015;37:1–2.
 9. Morris RK, Malin GL, Quinlan-Jones E, et al. Percutaneous 
vesicoamniotic shunting versus conservative management for fetal 
lower urinary tract obstruction (PLUTO): a randomised trial. Lancet 
2013;382:1496–506.
 10. Laptook AR, Shankaran S, Tyson JE, et al. Effect of Therapeutic 
Hypothermia Initiated After 6 Hours of Age on Death or Disability 
Among Newborns With Hypoxic-Ischemic Encephalopathy: A 
Randomized Clinical Trial. JAMA 2017;318:1550–60.
 11. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or 
transcatheter aortic-valve replacement in intermediate-risk patients. 
N Engl J Med 2017;376:1321–31.
 12. Pearse RM, Harrison DA, MacDonald N, et al. Effect of a 
perioperative, cardiac output-guided hemodynamic therapy 
algorithm on outcomes following major gastrointestinal surgery: 
a randomized clinical trial and systematic review. JAMA 
2014;311:2181–90.
 13. Grocott MP, Dushianthan A, Hamilton MA, et al. Perioperative 
increase in global blood flow to explicit defined goals and outcomes 








pen: first published as 10.1136/bmjopen-2018-024256 on 7 March 2019. Downloaded from 
